Structure Therapeutics Inc. (GPCR)

NASDAQ: GPCR · IEX Real-Time Price · USD
22.35
+1.14 (5.37%)
Mar 29, 2023, 4:30 PM EDT - Market closed
5.37%
Market Cap 817.75M
Revenue (ttm) n/a
Net Income (ttm) -40.01M
Shares Out 36.59M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 89,662
Open 21.99
Previous Close 21.21
Day's Range 21.58 - 23.55
52-Week Range 20.80 - 30.00
Beta n/a
Analysts n/a
Price Target 40.04 (+79.15%)
Earnings Date n/a

About GPCR

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular dis... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2023
Country United States
Stock Exchange NASDAQ
Ticker Symbol GPCR
Full Company Profile

Financial Performance

Financial Statements

News

Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therape...

1 month ago - GlobeNewsWire

Structure Therapeutics IPO prices at top of range with larger number of shares added in a sign of healthy investor interest

Structure Therapeutics Inc. GPCR, priced 10.74 million American depositary shares at $15 each to raise $161 million in its initial public offering with joint book-running managers Jefferies, SVB Secur...

1 month ago - Market Watch

Structure Therapeutics Announces Pricing of Upsized Initial Public Offering

SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...

1 month ago - GlobeNewsWire

Structure Therapeutics sets IPO terms, to be valued at up to $522 million

Structure Therapeutics Inc. has set terms for its initial public offering (IPO), as the California-based biopharmaceutical company developing oral therapeutics looks to raise up to $134.25 million. Th...

2 months ago - Market Watch

Chronic disease biotech Structure Therapeutics files for a $100 million IPO

Structure Therapeutics, a Phase 1 biotech developing G-protein-coupled receptors for chronic diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.

2 months ago - Renaissance Capital

Structure Therapeutics IPO Registration Document (S-1)

Structure Therapeutics has filed to go public with an IPO on the {Market}.

2 months ago - SEC.gov